Stratrix
On the Record · Revvity

Revvity acquisitions, on the record

The businesses Revvity bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
Applied, Food and Enterprise Services businesses (the "Business") sold to PerkinElmer Topco, L.P.
Word for word“On March 13, 2023, we completed the previously announced sale (the “Closing”) of certain assets and the equity interests of certain entities constituting our Applied, Food and Enterprise Services businesses (the “Business”) to PerkinElmer Topco, L.P.” 10-K for 2023
divestitureMarch 13, 2023—
BioLegend, Inc.
Word for word“In fiscal year 2021, t he Company completed the acquisition of BioLegend, Inc. ( “ BioLegend ” ) and paid an aggregate consideration of $ 5.7 billion, net of cash acquired of $ 292.4 million, reflecting working capital and other adjustments (the “ Aggregate Consideration ” ).” 10-K for 2023
acquisitionfiscal year 2021aggregate consideration of $ 5.7 billion, net of cash acquired of $ 292.4 million
Oxford Immunotec Global PLC
Word for word“The acquired businesses include Oxford Immunotec Global PLC, a company based in Abingdon, UK with approximately 275 employees, for total consideration of $ 590.9 million and Nexcelom Bioscience Holdings, LLC, a company based in Lawrence, Massachusetts with approximately 130 employees, for total consideration of $ 267.3 million, and five other businesses, which were acquired for total consideration of $ 318.6 million.” 10-K for 2023
acquisition—total consideration of $ 590.9 million
Nexcelom Bioscience Holdings, LLC
Word for word“The acquired businesses include Oxford Immunotec Global PLC, a company based in Abingdon, UK with approximately 275 employees, for total consideration of $ 590.9 million and Nexcelom Bioscience Holdings, LLC, a company based in Lawrence, Massachusetts with approximately 130 employees, for total consideration of $ 267.3 million, and five other businesses, which were acquired for total consideration of $ 318.6 million.” 10-K for 2023
acquisition—total consideration of $ 267.3 million
two businesses acquired in fiscal year 2022
Word for word“During fiscal year 2022, the Company completed the acquisition of two businesses for aggregate consideration of $ 13.3 million.” 10-K for 2023
acquisitionfiscal year 2022aggregate consideration of $ 13.3 million
the Business
Word for word“The results of discontinued operations during fiscal year 2023 include the results of the Business through March 13, 2023.” 10-K for 2024
divestitureMarch 13, 2023—
acquired businesses (not named in the text)
Word for word“During fiscal year 2023, purchases of investments in U.S. treasury securities amounted to $1.2 billion, and net cash used for acquisitions was $2.1 million, which were partially offset by proceeds from maturity of U.S. treasury securities totaling $550.0 million.” 10-K for 2024
acquisitionfiscal year 2023$2.1 million
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash received from selling businesses
2017-01-01$21 million
2017-12-31$1.1 million
2018-12-30$38 million
2019-12-29$550,000
2021-01-03$4.3 million
2022-01-02$1.6 million
2023-01-01$14.5 million
2023-12-31$153,000
2024-12-29$2.5 million
2025-12-28$304,000

Deal filings since 2016

Read from Revvity’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-24. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.